2025-07-14 - Analysis Report
Okay, here's an analysis of Natera Inc (NTRA) based on the provided data, structured as requested, and formatted for a concise English report.

### Natera Inc (NTRA) Stock Analysis

**Ticker:** NTRA
**Company Name:** Natera Inc.
**Company Overview:** Natera Inc. is a diagnostics company specializing in cell-free DNA testing for reproductive health, oncology, and organ health.

**1. Performance vs. S&P 500 (VOO)**

*   **NTRA Cumulative Return:** 126.35%
*   **VOO (S&P 500) Cumulative Return:** 95.76%
*   **Absolute Divergence:** 30.6%
*   **Relative Divergence:** 10.4 (On a scale of min/max divergence).
    *   **Analysis:** NTRA has outperformed the S&P 500. The relative divergence suggests that this outperformance is towards the lower end of its historical range.

**Alpha, Beta Analysis**

| Year       | CAGR    | MDD   | Alpha     | Beta | Cap(B) |
|------------|---------|-------|-----------|------|--------|
| 2015-2017  | -6.0%   | 62.4% | -31.0%    | 0.0  | 1.2    |
| 2016-2018  | 29.0%   | 80.1% | 11.0%     | 0.0  | 1.9    |
| 2017-2019  | 159.0%  | 80.1% | 130.0%    | 1.2  | 4.6    |
| 2018-2020  | 530.0%  | 80.1% | 510.0%    | 0.3  | 13.6   |
| 2019-2021  | 355.0%  | 62.9% | 307.0%    | 0.2  | 12.7   |
| 2020-2022  | -119.0% | 62.9% | -121.0%   | 0.2  | 5.5    |
| 2021-2023  | -482.0% | 69.9% | -500.0%   | 1.1  | 8.5    |
| 2022-2024  | -75.0%  | 70.6% | -100.0%   | 1.2  | 21.6   |
| 2023-2025  | 75.0%   | 72.8% | 28.0%     | 0.8  | 21.9   |

*   **Analysis:**
    *   **CAGR:** Wide range, reflecting high volatility.
    *   **MDD:** Consistently high Maximum Drawdown, indicating significant risk.
    *   **Alpha:**  Significant alpha values in periods of strong growth, and negative alpha in periods of underperformance.
    *   **Beta:** Beta values varies with the time, generally low beta suggests less sensitivity to overall market movements.

**2. Recent Stock Price Movement**

*   **Current Price:** 160.43
*   **Last Market Data:** Price: 160.13, Previous Close: 160.43, Change: -0.19
*   **5-Day Moving Average:** 160.54
*   **20-Day Moving Average:** 165.35
*   **60-Day Moving Average:** 158.84

*   **Analysis:** The price is slightly below the 5-day moving average and significantly below the 20-day moving average, suggesting a recent downward trend. The price is above 60-Day Moving Average. The last market data showing a slight decrease.

**3. Market Risk Indicators and Expected Return**

*   **MRI (Market Risk Indicator):** 0.3294 (Low Risk)
*   **RSI (Relative Strength Index):** 34.44 (Approaching oversold territory)
*   **PPO (Percentage Price Oscillator):** -0.66 (Slightly bearish)
*   **Hybrid Signal:** Cash 70%, Sell 0.2% of holdings (Caution)
*   **Recent Relative Divergence Change (20-day):** 0.0 (Neutral)
*   **Expected Return:** 164.2% (Long-term, relative to S&P 500)

*   **Analysis:** The MRI indicates low market risk. The RSI suggests the stock might be oversold. PPO is bearish. The hybrid signal advises caution. The high expected return suggests potential long-term outperformance.

**4. Recent News & Significant Events**

*   **2025-07-10:** Major business developments, regulatory changes, or market events.
*   **2025-07-13:** Analysts discussing performance in the context of industry trends and global economic factors.
*   **2025-07-14:** Notable stock volatility influenced by recent news, earnings reports, or executive actions.
*   **2025-07-11:** Market experts highlight risks and opportunities.

*   **Analysis:** Recent news suggests a dynamic environment with both risks and opportunities influencing stock volatility.

**5. Recent Earnings Analysis**

| 날짜         | EPS    | 매출        |
|--------------|--------|-------------|
| 2025-05-09   | -0.5   | 0.50 B$     |
| 2024-11-12   | -0.26  | 0.44 B$     |
| 2024-08-09   | -0.3   | 0.41 B$     |
| 2024-05-10   | -0.56  | 0.37 B$     |
| 2025-05-09   | -0.56  | 0.37 B$     |

*   **Analysis:** Consistent negative EPS (Earnings Per Share), but revenue shows an upward trend.  The duplicate entry in 2025-05-09 should be verified.

**6. Financial Information**

**Revenue and Profitability**

| Quarter    | Revenue | Profit Margin |
|------------|---------|---------------|
| 2025-03-31 | $0.50B  | 63.12%        |
| 2024-12-31 | $0.48B  | 62.94%        |
| 2024-09-30 | $0.44B  | 61.79%        |
| 2024-06-30 | $0.41B  | 58.83%        |
| 2024-03-31 | $0.37B  | 56.72%        |

**Capital and Profitability**

| Quarter    | Equity  | ROE       |
|------------|---------|-----------|
| 2025-03-31 | $1.24B  | -5.40%    |
| 2024-12-31 | $1.20B  | -4.50%    |
| 2024-09-30 | $0.88B  | -3.60%    |
| 2024-06-30 | $0.84B  | -4.48%    |
| 2024-03-31 | $0.79B  | -8.51%    |

*   **Analysis:**
    *   **Revenue:**  Shows consistent growth.
    *   **Profit Margin:**  Strong and increasing.
    *   **Equity:**  Increasing.
    *   **ROE (Return on Equity):**  Negative, indicating the company is not generating profit from shareholder equity.

**7. Overall Analysis**

Natera Inc. exhibits strong revenue growth and impressive profit margins, but it's currently not profitable, as indicated by negative EPS and ROE. The stock has outperformed the S&P 500, but recent price action suggests a possible short-term downward trend.  The MRI indicates a low-risk market environment, but the hybrid signal advises caution. The high expected return suggests potential for long-term outperformance, but this is contingent on the company achieving profitability.  Recent news indicates a dynamic environment with both risks and opportunities, so investors should closely monitor company announcements and industry trends. Overall, NTRA appears to be a high-growth, high-risk investment opportunity.
